newsfilter
← Latest News
GlobeNewswire·

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447